| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/21/2004 | EP1409655A2 Immunoglobulin superfamily proteins |
| 04/21/2004 | EP1409654A1 Immunological control of beta-amyloid levels in vivo |
| 04/21/2004 | EP1409653A1 Viral mutants that selectively replicate in targeted human cancer cells |
| 04/21/2004 | EP1409648A1 New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions |
| 04/21/2004 | EP1409639A1 Epidermal growth factor receptorantisense oligonucleotides |
| 04/21/2004 | EP1409551A2 Chimeric capsid proteins and uses thereof |
| 04/21/2004 | EP1409550A1 Extracellular messengers |
| 04/21/2004 | EP1409549A2 Compositions and methods for the diagnosis and treatment of tumor |
| 04/21/2004 | EP1409542A2 Blood group antigen fusion polypeptides and methods of use thereof |
| 04/21/2004 | EP1409540A2 Melanocortin receptor ligands |
| 04/21/2004 | EP1409539A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 04/21/2004 | EP1409536A2 Human proteins and nucleic acids encoding same |
| 04/21/2004 | EP1409535A2 Human secreted proteins |
| 04/21/2004 | EP1409534A2 Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof |
| 04/21/2004 | EP1409532A2 Moringa seed proteins |
| 04/21/2004 | EP1409531A2 Heterocarpine, a human ghrh-binding protein |
| 04/21/2004 | EP1409526A2 An inducer of apoptosis |
| 04/21/2004 | EP1409524A2 Target for antiviral therapy |
| 04/21/2004 | EP1409523A2 Pancam nucleic acids and polypeptides |
| 04/21/2004 | EP1409522A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 04/21/2004 | EP1409521A2 Cyclic peptides as potent and selective melanocortin-4 receptor agonists |
| 04/21/2004 | EP1409520A2 Vegfr-3 inhibitor materials and methods |
| 04/21/2004 | EP1409519A1 Lipid-peptide conjugates for treatment of cancer |
| 04/21/2004 | EP1409518A1 Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis |
| 04/21/2004 | EP1409516A2 Aromatic sulfenates for type i phototherapy |
| 04/21/2004 | EP1409515A1 Process for extracting collagen from marine invertebrates |
| 04/21/2004 | EP1409510A2 Biological pacemaker |
| 04/21/2004 | EP1409509A2 Antisense modulation of c-reactive protein expression |
| 04/21/2004 | EP1409508A2 Mammalian neuralized family transcriptional regulators and uses therefor |
| 04/21/2004 | EP1409466A2 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
| 04/21/2004 | EP1409016A2 Antibodies to opgl |
| 04/21/2004 | EP1409015A1 Methods for treating or preventing skin disorders using cd2-binding agents |
| 04/21/2004 | EP1409008A1 Use of the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent |
| 04/21/2004 | EP1409007A2 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 04/21/2004 | EP1409006A2 Methods of treating diabetes mellitus |
| 04/21/2004 | EP1409005A1 Modulators of notch signalling for use in immunotherapy |
| 04/21/2004 | EP1409003A2 Methods for reducing immunogenicity of polypeptides |
| 04/21/2004 | EP1408988A1 Compositions of orally administered nutritional supplements to repair articular cartilage |
| 04/21/2004 | EP1408956A1 Uses of metal salts to stabilize taxane-based compositions |
| 04/21/2004 | EP1408942A1 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 04/21/2004 | EP1408930A1 Microemulsion preconcentrates which contain cyclosporines and corresponding microemulsions |
| 04/21/2004 | EP1408876A1 Zero-order prolonged release coaxial implants |
| 04/21/2004 | EP1408808A2 Methods for diagnosing and treating heart disease |
| 04/21/2004 | EP1408759A2 Human secreted proteins |
| 04/21/2004 | EP1408753A2 Compounds effecting neuron remodeling and assays for same |
| 04/21/2004 | EP1287355B1 Methods and compounds for influencing beta3 integrin-dependent intracellular processes |
| 04/21/2004 | EP1262065A4 Method and system for providing a customized media list |
| 04/21/2004 | EP1257577B1 Process for solubilizing glucagon-like peptide 1 (glp-1) compounds |
| 04/21/2004 | EP1181036A4 Pharmaceutical compositions of erythropoietin |
| 04/21/2004 | EP1018341B1 Antistress agents and functional foods |
| 04/21/2004 | EP1007065B1 Preparation of collagen |
| 04/21/2004 | EP0989858B1 Cd28/ctla-4 inhibiting peptidomimetics and pharmaceutical compositions thereof |
| 04/21/2004 | EP0973542A4 Biological pesticide |
| 04/21/2004 | EP0859847B1 Composition and method of imparting resistivity to hiv superinfection to cells |
| 04/21/2004 | EP0857068B1 Immunotherapy of cancer and infectious disease using antigen-presenting cells sensitized with heat shock protein-antigen complexes |
| 04/21/2004 | EP0856007B1 Cyclopeptide derivatives |
| 04/21/2004 | EP0836647B1 Antiviral proteins, dna coding sequences therefor, and uses thereof |
| 04/21/2004 | EP0815218B1 Human vegf-specific antisense oligonucleotides |
| 04/21/2004 | EP0714406B1 Refolding of polypeptides like recombinant insulin-like growth factor igf-i |
| 04/21/2004 | EP0641215B1 Protease-resistant thrombomodulin analogs |
| 04/21/2004 | CN1491280A Synovial membrane cell protein |
| 04/21/2004 | CN1491233A Long lasting growth hormone releasing factor derivatives |
| 04/21/2004 | CN1491232A Modified leptin with reduced immunogenicity |
| 04/21/2004 | CN1491231A Modified keratinocyte growth factor (KGF) with reduced immunogenicity |
| 04/21/2004 | CN1491117A Compositions containing inclusion complexes |
| 04/21/2004 | CN1491115A Use of botulinum toxin for treatment of articular pathologies |
| 04/21/2004 | CN1491114A Compositions for nasal administration of insulin |
| 04/21/2004 | CN1491099A Use of [š�-hydroxy-N-methyl-L-leucine9] cyclosporin A for hair growth |
| 04/21/2004 | CN1490410A High effective expression of recombined human internal inhibition factor |
| 04/21/2004 | CN1490333A Insulinotropic peptide and its use |
| 04/21/2004 | CN1490329A Imidazoline substituted phenoxyacetyl oligopeptide compounds, their synthesis and medical uses |
| 04/21/2004 | CN1490328A Imidazoline substituted phenoxyacetyl oligopeptide compounds, their synthesis and medical uses |
| 04/21/2004 | CN1490050A Hepatitis A inactivated vaccine |
| 04/21/2004 | CN1490049A CD26/DPP IV application for medicine in preparing treatment and/or diagnostic disease |
| 04/21/2004 | CN1490048A Method for improving oral drug living thing availability, composition and reagent box |
| 04/21/2004 | CN1146665C Method of modulating melanin synthesis |
| 04/21/2004 | CN1146664C Fusion polypeptides comprising and IgE-binding domain and HSA component, and their diagnostic and therapeutic uses |
| 04/21/2004 | CN1146576C Proteins from mammaliam liver and their use in oncology |
| 04/21/2004 | CN1146575C Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| 04/21/2004 | CN1146445C Materials and methods relating to diagnosis and treatment of pre-eclampsia and diabetes |
| 04/21/2004 | CN1146442C Lympha toxin-alpha/beta compositions as anti tumor agent and antilympha toxin beta receptor antibody |
| 04/21/2004 | CN1146441C Composition of containing lympha toxin beta receptor |
| 04/21/2004 | CN1146440C Vascular endothelial growth factor-B |
| 04/21/2004 | CN1146418C Fixed-dose association of angiotensin-converting enzyme inhibitor and of calcium channel antagonist, method for preparation and use thereof in treatment of cardivas cular illnesses |
| 04/21/2004 | CN1146417C Stabilized pharmaceutical compositions, with quinupristine and dalfopristine base and their prepn |
| 04/21/2004 | CN1146414C Amino acid composition and use thereof in immunosuppression |
| 04/21/2004 | CN1146408C Novel poly(methylidene malonate) microspheres, preparation method and pharmaceutical compositions containing them |
| 04/21/2004 | CN1146403C Active substance releasing system |
| 04/21/2004 | CN1146402C Gel composition and method of preparing the composition |
| 04/20/2004 | US6723893 Mice having a mutant SOD-1-encoding transgene |
| 04/20/2004 | US6723841 Corticotropin-releasing factor2 receptors |
| 04/20/2004 | US6723832 Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof |
| 04/20/2004 | US6723831 Removal antibodies from body fluids |
| 04/20/2004 | US6723830 Short peptides which selectively modulate the activity of protein kinases |
| 04/20/2004 | US6723706 Modified antisense nucleotides complementary to a section of the human Ha-ras gene |
| 04/20/2004 | US6723705 Gene expression; activating t-cells ability to bind cd28 or ctla4 ligands; antimetastasis and anticarcinogenic agents |
| 04/20/2004 | US6723703 Administering powder or aerosol to nasal mucosa and osteomeatal complex |
| 04/20/2004 | US6723702 Use of relaxin treat diseases related to vasoconstriction |
| 04/20/2004 | US6723701 Having different amino acid sequence or chemically modified so the isoelectric point is lower to improve bioavailability relative the unmodified cationic polypeptide; dna; expression vectors; transformed cells; treating neuropathies |
| 04/20/2004 | US6723700 Polypeptide increase blood/brain barrier permeability |